EAU 2014 - Poster: Cost-utility analysis of onabotulinumtoxinA vs best supportive care in the treatment of idiopathic overactive bladder with urinary incontinence among patients not adequately managed with anticholinergic therapy

STOCKHOLM, SWEDEN (UroToday.com) - Presented by Nick Freemantle,1 Kristin Khalaf,2 Daisy Ng-Mak,2,* Clara Loveman,3 Sanja Stanisic,4 Dmitry Gultyaev,5 Johanna Lister,5 and Marcus Drake6 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

Poster--Cost-utility EAU thumb

1Department of Primary Care and Population Health, UCL Medical School, London, United Kingdom; 2Allergan Inc., Irvine, CA, USA; 3Allergan Ltd, Marlow, United Kingdom; 4LA-SER ANALYTICA, Milan, Italy; 5LA-SER ANALYTICA, Lörrach, Germany; 6Department of Urology, Southmead Hospital, Bristol, United Kingdom *Currently Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

 

APCCC 2021 read now


email news signup